Digital Media briefs

Share this article:
Bayer HealthCare has launched a customizable mobile app for patients with hemophilia A. The app, available for iPhone, iPod Touch and iPad as a free download at, aims to make tracking and recording hemophilia factor VIII infusions easier and to capture dosing history, frequency and location of bleeds, displaying an alert when it's time for another infusion.

Women outnumber men two to one in using the internet for initial research on aches and pains, according to a 500-person survey by Flexcin International. The survey found that nearly three-quarters of women use the internet for initial research compared to just 44% of men—in part because women grow tired of the frustrations of trying to see their doc, while men have trouble describing their pain.

Display ads online are on the rebound, with impressions up 15% year-on-year, according to comScore, and flash and rich media ads account for 40% of US impressions. “One of the several drivers of strength in this market has been the innovation occurring with respect to ad units, as larger and more engaging creative ad formats are employed,” said comScore SVP Jeff Hackett.
Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Features

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?